The acquisition will enable Quintiles’ customers to use genomic services to better understand diseases, develop diagnostic tools and deliver safer, more effective therapies.

Quintiles Global Laboratories senior vice president Thomas Wollman said the addition of Expression Analysis’ Genomic Know-How to the company is another step forward in its efforts to bring personalized medicine into mainstream drug development.

"Its expertise in genetic sequencing and advanced bioinformatics is essential to understanding diseases and drugs at the molecular level," Wollman added.

The terms of the deal have not been disclosed.

Expression Analysis president and chief executive officer Steve McPhail said, "The combination of Quintiles Global Laboratories and EA genomic technology excellence will facilitate worldwide access to resources and expertise to drive improvements in the diagnosis, treatment and management of complex disease."